Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
NCT ID: NCT04930653
Last Updated: 2025-10-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
34 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-10-19
Study Completion Date
2028-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
NCT04185220
Adult T-Cell Lymphoma/Leukemia
Sezary Syndrome
Mycosis Fungoides
COMPLETED
PHASE1
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
NCT06569680
Extranodal Marginal Zone Lymphoma
RECRUITING
PHASE2
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
NCT00109863
Melanoma (Skin)
COMPLETED
PHASE2
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
+10 more
ACTIVE_NOT_RECRUITING
PHASE1
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
NCT01082198
Melanoma (Skin)
UNKNOWN
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
I. To assess tolerability and overall response rate (ORR) of the (ECP)/mogamulizumab regimen in CTCL patients previously untreated with mogamulizumab.
SECONDARY OBJECTIVES:
I. To estimate complete response (CR) rate, time to response, duration of response, progression free survival, and overall survival in CTCL patients treated with the ECP/mogamulizumab combination.
II. To summarize the toxicities in CTCL patients treated with the ECP/mogamulizumab combination.
EXPLORATORY OBJECTIVES:
I. To assess quality of life (QoL) parameters before, during, and after the regimen.
II. To evaluate the anti-tumor and immunomodulatory effects of mogamulizumab in the CTCL microenvironment in skin and blood samples of erythrodermic CTCL patients.
III. To evaluate the immunomodulatory effects of ECP.
OUTLINE:
Patients receive mogamulizumab intravenously (IV) over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR)/partial response (PR) after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then for up to 12 months.
I. To assess tolerability and overall response rate (ORR) of the (ECP)/mogamulizumab regimen in CTCL patients previously untreated with mogamulizumab.
SECONDARY OBJECTIVES:
I. To estimate complete response (CR) rate, time to response, duration of response, progression free survival, and overall survival in CTCL patients treated with the ECP/mogamulizumab combination.
II. To summarize the toxicities in CTCL patients treated with the ECP/mogamulizumab combination.
EXPLORATORY OBJECTIVES:
I. To assess quality of life (QoL) parameters before, during, and after the regimen.
II. To evaluate the anti-tumor and immunomodulatory effects of mogamulizumab in the CTCL microenvironment in skin and blood samples of erythrodermic CTCL patients.
III. To evaluate the immunomodulatory effects of ECP.
OUTLINE:
Patients receive mogamulizumab intravenously (IV) over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR)/partial response (PR) after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then for up to 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Folliculotropic Mycosis Fungoides
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Sezary Syndrome
Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
Transformed Mycosis Fungoides
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (ECP, mogamulizumab)
Patients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Extracorporeal Photopheresis
Intervention Type
PROCEDURE
Undergo ECP
Mogamulizumab
Intervention Type
BIOLOGICAL
Given IV
Quality-of-Life Assessment
Intervention Type
OTHER
Ancillary studies
Questionnaire Administration
Intervention Type
OTHER
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extracorporeal Photopheresis
Undergo ECP
Intervention Type
PROCEDURE
Mogamulizumab
Given IV
Intervention Type
BIOLOGICAL
Quality-of-Life Assessment
Ancillary studies
Intervention Type
OTHER
Questionnaire Administration
Ancillary studies
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Extracorporeal Photophoresis
photopheresis
Photophoresis
Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer
KM8761
KW-0761
Mogamulizumab-kpkc
Poteligeo
Quality of Life Assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented informed consent of the participant and/or legally authorized representative
* Assent, when appropriate, will be obtained per institutional guideline
* Agreement to allow the use of archival tissue from diagnostic tumor biopsies
* If unavailable, exceptions may be granted with study principal investigator (PI) approval
* Age: \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) =\< 2
* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS). Safety lead-in: \>= stage IIB OR \>= stage IB-IIA folliculotropic/transformed MF. Phase 2: \>= stage IB
* Stage of disease according to Tumor-Node-Metastasis-Blood (TNMB) classification
* Pathology report must be diagnostic or be consistent with MF/SS criteria
* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria
* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used.
* Measurable disease per Modified Severity Weighted Assessment Tool (mSWAT) and/or Sezary count
* Baseline skin biopsy taken within 6 months available for central review submission
* Without bone marrow involvement: Absolute neutrophil count (ANC) \>= 1,500/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* With bone marrow involvement: ANC \>= 1,000/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* Without bone marrow involvement: Platelets \>= 100,000/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
* With bone marrow involvement: Platelets \>= 75,000/mm3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Aspartate aminotransferase (AST) =\< 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Alanine aminotransferase (ALT) =\< 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Creatinine clearance of \>= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease) (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =\< 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Hepatitis C virus (HCV)\*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \[RPR\])
* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
* Meets other institutional and federal requirements for infectious disease titer requirements
* Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
* Subjects with MF and a history of staphylococcus colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics
* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy
* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
* Assent, when appropriate, will be obtained per institutional guideline
* Agreement to allow the use of archival tissue from diagnostic tumor biopsies
* If unavailable, exceptions may be granted with study principal investigator (PI) approval
* Age: \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) =\< 2
* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS). Safety lead-in: \>= stage IIB OR \>= stage IB-IIA folliculotropic/transformed MF. Phase 2: \>= stage IB
* Stage of disease according to Tumor-Node-Metastasis-Blood (TNMB) classification
* Pathology report must be diagnostic or be consistent with MF/SS criteria
* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria
* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used.
* Measurable disease per Modified Severity Weighted Assessment Tool (mSWAT) and/or Sezary count
* Baseline skin biopsy taken within 6 months available for central review submission
* Without bone marrow involvement: Absolute neutrophil count (ANC) \>= 1,500/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* With bone marrow involvement: ANC \>= 1,000/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* Without bone marrow involvement: Platelets \>= 100,000/mm\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
* With bone marrow involvement: Platelets \>= 75,000/mm3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Aspartate aminotransferase (AST) =\< 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Alanine aminotransferase (ALT) =\< 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Creatinine clearance of \>= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease) (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =\< 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)
* Hepatitis C virus (HCV)\*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \[RPR\])
* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
* Meets other institutional and federal requirements for infectious disease titer requirements
* Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
* Subjects with MF and a history of staphylococcus colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics
* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy
* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
Exclusion Criteria
* Prior mogamulizumab
* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy
* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
* Any skin-directed therapy within 14 days prior to initiating protocol therapy
* Any radiation therapy within 21 days prior to initiating protocol therapy
* Immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:
* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days
* Systemic corticosteroids at physiologic doses of \< 10 mg/day of prednisone or equivalent
* Live, attenuated vaccine within 30 days prior to the first dose protocol therapy
* Disease free of prior malignancies for \>= 5 years with the exception of:
* Currently treated squamous cell and basal cell carcinoma of the skin, or
* Carcinoma in situ of the cervix, or
* Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision, or
* Prostate cancer (T1a or T1b using the TNM \[tumor, nodes, metastasis\] clinical staging system) that has/have been surgically cured, or
* Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
* Active infection requiring antibiotics
* Known hepatitis B or hepatitis C infection
* Other active malignancy
* Females only: Pregnant or breastfeeding
* Prior stem cell transplantation
* Acute infection requiring systemic treatment
* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy
* Renal failure requiring hemodialysis or peritoneal dialysis
* Unstable cardiac disease as defined by one of the following:
* Cardiac events such as myocardial infarction (MI) within the past 6 months
* NYHA (New York Heart Association) heart failure class III-IV
* Uncontrolled atrial fibrillation or hypertension
* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
* Vitiligo or alopecia
* Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or
* Psoriasis not requiring systemic treatment
* History of primary immunodeficiency
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy
* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy
* Any skin-directed therapy within 14 days prior to initiating protocol therapy
* Any radiation therapy within 21 days prior to initiating protocol therapy
* Immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:
* Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days
* Systemic corticosteroids at physiologic doses of \< 10 mg/day of prednisone or equivalent
* Live, attenuated vaccine within 30 days prior to the first dose protocol therapy
* Disease free of prior malignancies for \>= 5 years with the exception of:
* Currently treated squamous cell and basal cell carcinoma of the skin, or
* Carcinoma in situ of the cervix, or
* Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision, or
* Prostate cancer (T1a or T1b using the TNM \[tumor, nodes, metastasis\] clinical staging system) that has/have been surgically cured, or
* Any other malignancy that has/have been curatively treated with surgery and/or localized radiation
* Active infection requiring antibiotics
* Known hepatitis B or hepatitis C infection
* Other active malignancy
* Females only: Pregnant or breastfeeding
* Prior stem cell transplantation
* Acute infection requiring systemic treatment
* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy
* Renal failure requiring hemodialysis or peritoneal dialysis
* Unstable cardiac disease as defined by one of the following:
* Cardiac events such as myocardial infarction (MI) within the past 6 months
* NYHA (New York Heart Association) heart failure class III-IV
* Uncontrolled atrial fibrillation or hypertension
* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
* Vitiligo or alopecia
* Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or
* Psoriasis not requiring systemic treatment
* History of primary immunodeficiency
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
City of Hope Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christiane R Querfeld
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Scottsdale, Arizona, United States
Site Status
RECRUITING
City of Hope Medical Center
Duarte, California, United States
Site Status
RECRUITING
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-03533
Identifier Type: REGISTRY
Identifier Source: secondary_id
20724
Identifier Type: OTHER
Identifier Source: secondary_id
20724
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma
NCT00016055
UNKNOWN
PHASE1
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
NCT01087333
RECRUITING
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
NCT03304639
ACTIVE_NOT_RECRUITING
PHASE2
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338
COMPLETED
PHASE1
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NCT03901573
TERMINATED
PHASE1/PHASE2
Interleukin-2 in Treating Patients With Mycosis Fungoides
NCT00002687
COMPLETED
PHASE1
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
NCT00052377
TERMINATED
PHASE1/PHASE2
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
NCT00704938
TERMINATED
PHASE2
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT00871481
COMPLETED
PHASE1/PHASE2
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
NCT00005788
TERMINATED
PHASE2
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
NCT02584829
TERMINATED
PHASE1/PHASE2
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT02668770
ACTIVE_NOT_RECRUITING
PHASE1
Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00045357
COMPLETED
PHASE1
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
NCT02350673
COMPLETED
PHASE1
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
NCT00091104
COMPLETED
PHASE1
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
NCT06056895
ACTIVE_NOT_RECRUITING
PHASE2
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
NCT02556463
TERMINATED
PHASE1
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
NCT04551352
COMPLETED
PHASE1
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
NCT02153905
TERMINATED
PHASE1/PHASE2
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
NCT02890368
TERMINATED
PHASE1
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
NCT05034536
ACTIVE_NOT_RECRUITING
PHASE2
Safety of Intranodal ECI-006 in Melanoma Patients
NCT03394937
TERMINATED
PHASE1
Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
NCT01579318
TERMINATED
PHASE2
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
NCT01026051
TERMINATED
PHASE2